THALES
14.9.2021 09:02:12 CEST | Business Wire | Press release
COVID-19 quickly ushered in the era of remote work, introducing new risks that IT professionals are struggling to manage with existing security tools, according to a new Thales study. Six in 10 respondents said traditional security tools such as VPNs are still the primary vehicle for employees accessing applications remotely -- likely the reason why almost half (44%) were not confident that their access security systems could scale effectively to secure remote work.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210914005014/en/
These are among the key insights from the 2021 Thales Access Management Index , a global survey of 2,600 IT decision makers, commissioned by Thales and conducted by 451 Research, part of S&P Global Market Intelligence, to better understand the new security risks and challenges caused by the rise of remote working and cloud transformation caused by the COVID-19 pandemic.
Last year saw a surge in cybercrime exploiting the various aspects of the COVID-19 pandemic and the shift to remote work, with ransomware attacks soaring by 150%.1 The Thales survey found the pandemic’s effects have had a significant impact on security infrastructure, particularly on access management and authentication frameworks, pushing organisations to adopt modern security strategies like Zero Trust to support the demands of a more mobile and remote workforce.
Era of Remote Working – Concerns Catalyse Change
According to the index, respondents have many different systems deployed for remote access. When asked about the technologies that were in place, VPN was the most common, with 60% of IT professionals identifying the capability. Virtual Desktop Infrastructure, cloud-based access and Zero Trust network access/software defined perimeter (ZTNA/SDP) closely followed. However, when asked what new access technologies respondents were planning to deploy due to the pandemic, nearly half (44%) indicated ZTNA/SDP was the top technology choice.
Thales also explored respondents’ plans to move beyond traditional VPN environments, and found that nearly 40% expect to replace their VPN with ZTNA/SDP, while 38% expect to move to a Multi-Factor Authentication (MFA) solution. This confirms the need for more modern, sophisticated authentication capabilities is driving change in many organisations and is perceived as a key enabler of Zero Trust security.
“Seemingly overnight, remote access went from being an exception to the default working model for a large swath of employees. As a result, businesses are navigating a volatile and complex world, and adopting a Zero Trust model of cybersecurity will enable them to continue to conduct operations safely amidst the uncertainty,” said Francois Lasnier, vice president of Access Management solutions at Thales . “One of the core barrier businesses face when starting their Zero Trust journey is the balance between locking down access without interrupting workflow. People require access to sensitive data in order to work and collaborate and businesses leaders will need to ensure that a drop in productivity doesn’t become an unwanted side effect. The research shows that IT professionals increasingly see access management and modern authentication capabilities as key component in achieving a Zero Trust model.”
Room to Grow with Zero Trust
The Thales report found that Zero Trust models are the solution of choice for respondents seeking to improve access environments, yet many are still in the early stage of adoption.
According to the research, less than a third (30%) of the respondents claim to have a formal strategy and have actively embraced a Zero Trust policy. Additionally, almost half (45%) are either planning, researching or considering a Zero Trust strategy. Surprisingly, less than a third (32%) of the respondents indicated that Zero Trust shapes their cloud security strategy to a great extent.
Access Security Needs to Adapt to Deal with Dynamic Workplaces
A silver lining of the pandemic-driven rush to remote working is the acceleration of improved approaches to access security. Thales found that 55% of respondents currently have adopted two-factor authentication within their organisations. Regionally, there was notable variation, with the UK leading (64%), followed by the U.S. (62%), APAC (52%) and LATAM (40%). These varying degrees of adoption may be due to the level at which better access management is prioritised in security investments.
Yet, despite the well-known limitations of passwords, investment in MFA still trails other security tools like firewalls, endpoint security, SIEM and email security. Remote access users are still the main use case for MFA adoption (71%). One-third of respondents that have adopted MFA use more than three different authentication tools, signaling the need for a more unified approach to access management in the future.
“Security tools and approaches need to adapt to better support the era of remote working,” said Eric Hanselman, chief analyst at 451 Research, part of S&P Global Market Intelligence . “The shift towards a Zero Trust model, along with increasing use of modern authentication technologies, like adaptive and multifactor authentication (MFA), will improve organisations’ security posture. This will be an exciting space to watch as businesses continue to deal with dynamic workplace environments.” 2
Thales and 451 Research will discuss the global findings in more detail during its upcoming Trusted Access Summit on 5 October 2021. To join, please visit the registration page .
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
PLEASE VISIT
1
Group-IB Ransomware Uncovered 2020-2021
2
Quote from Thales 2021 Global Access Management Index
View source version on businesswire.com: https://www.businesswire.com/news/home/20210914005014/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release
Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
